In March 2015 we completed a 3-part transaction with Novartis which reshapes our business. We acquired Novartis's vaccines business (excluding influenza vaccines) and combined our Consumer Healthcare businesses to create a new company. In addition, Novartis acquired our marketed Oncology portfolio and the R&D activities related to it.
As the integration of this business units progresses, this website will be updated to reflect the expanded portfolio of vaccines and consumer healthcare products.
GSK's prescription medicines target five major disease areas - respiratory illnesses, diabetes, viral control, infections, and central nervous system disorders.
GSK offers more than 25 vaccines worldwide to prevent potentially life-threatening or crippling illnesses such as Hepatitis A and B, diphtheria, tetanus, whooping cough, measles, mumps, rubella, polio, typhoid, influenza and bacterial meningitis.
GSK Consumer Healthcare brings dental health products, over-the-counter medicines and nutritional drinks to millions of people around the world.
Launched by The GlaxoSmithKline Foundation in partnership with the Canadian Hospice Palliative Care Association, the Living Lessons® program is a national initiative providing resources for patients, caregivers and health-care professionals involved with end-of-life care.
A Leading Canadian Manufacturer
GlaxoSmithKline maintains three state-of-the-art manufacturing facilities that produce innovative medicines and vaccines for patients in Canada and around the world. More than 75 medicines and 60 million units are produced annually at the Mississauga facility. Approximately 80 per cent of the production is exported to more than 100 markets worldwide.